Innovation follows laboratory work on its way to application: what stage a technology has reached, which problems remain unsolved, and how many years typically separate a demonstration from something purchasable. Hype cycles are named as such. For investors, researchers and readers tracking developments that are genuinely near-term.
AlphaFold solved a fifty-year problem of predicting protein shapes from their sequences — and the harder questions it exposed are about dynamics, interactions, and what laboratories still must do.
Replacing a battery's liquid electrolyte with a solid promises safer, denser electric vehicles — but dendrites, interfaces, and manufacturing stand in the way.
Standard CRISPR cuts both strands of DNA and waits for the cell to repair the break; base and prime editing rewrite letters directly, with far fewer cuts — and different risks.
Microfluidic chips that shrink a wet laboratory onto a slip of plastic and glass have already changed infectious disease testing — and their hardest problems are now economic, not physical.
Machines that read the body's faint magnetic fields have moved from physics laboratories into early clinical studies, though regulatory approval remains limited.